- Home
- UP vs PCRX Comparison
UP vs PCRX Comparison
Compare UP & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UP
- PCRX
- Stock Information
- Founded
- UP 2013
- PCRX 2006
- Country
- UP United States
- PCRX United States
- Employees
- UP N/A
- PCRX N/A
- Industry
- UP Aerospace
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- UP Consumer Discretionary
- PCRX Health Care
- Exchange
- UP Nasdaq
- PCRX Nasdaq
- Market Cap
- UP 1.4B
- PCRX 1.2B
- IPO Year
- UP N/A
- PCRX 2011
- Fundamental
- Price
- UP $1.30
- PCRX $22.17
- Analyst Decision
- UP
- PCRX Buy
- Analyst Count
- UP 0
- PCRX 5
- Target Price
- UP N/A
- PCRX $32.40
- AVG Volume (30 Days)
- UP 5.6M
- PCRX 532.2K
- Earning Date
- UP 11-05-2025
- PCRX 11-06-2025
- Dividend Yield
- UP N/A
- PCRX N/A
- EPS Growth
- UP N/A
- PCRX N/A
- EPS
- UP N/A
- PCRX N/A
- Revenue
- UP $765,885,000.00
- PCRX $705,848,000.00
- Revenue This Year
- UP $174.46
- PCRX $7.27
- Revenue Next Year
- UP N/A
- PCRX $10.18
- P/E Ratio
- UP N/A
- PCRX N/A
- Revenue Growth
- UP N/A
- PCRX 2.25
- 52 Week Low
- UP $0.74
- PCRX $16.00
- 52 Week High
- UP $3.50
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- UP 35.12
- PCRX 44.26
- Support Level
- UP $1.41
- PCRX $20.84
- Resistance Level
- UP $1.70
- PCRX $21.90
- Average True Range (ATR)
- UP 0.12
- PCRX 0.90
- MACD
- UP -0.02
- PCRX 0.06
- Stochastic Oscillator
- UP 4.76
- PCRX 64.33
About UP Wheels Up Experience Inc.
Wheels Up Experience Inc is a provider of on-demand private aviation in the United States. It is pioneering data and technology-driven solutions that connect consumers to safety-vetted and verified private aircraft. It connects private flyers to aircraft, and one another, through an open platform that enables life's most important experiences. Its offering is delivered through a mix of programmatic and charter options that strategically utilize its owned and leased aircraft fleet and an "asset-light" charter model to deliver a greater range of global travel alternatives. The company operates in a single operating and reportable segment, private aviation services. Geographically the company generates the majority of its revenue from the United States.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.